TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of a Home-based Exercise Program on Functional Capacity and Quality of Life in Heart Failure Patients
Brief Summary: Heart failure (HF) is a multisystemic disease leading to exercise intolerance and fatigue. Supervised physical training improves functional capacity, quality of life and reduces hospital admissions in HF patients. In this way, home physical training may be a good alternative to patients who, for any reason, cannot perform supervised training. Objective: To asses the effects of a home-based training program on functional capacity, sedentary lifestyle and quality of life of patients with chronic HF compared to supervised training.


Options:
A: Arm Label: Homebased cardiac rehabilitation program; Type: EXPERIMENTAL; Interventions: Device: Homebased cardiac rehabilitation program, Other: Traditional cardiac rehabilitation program | Arm Label: Traditional cardiac rehabilitation; Type: OTHER; Interventions: Other: Traditional cardiac rehabilitation program | Intervention Type: DEVICE; Name: Homebased cardiac rehabilitation program; Assigned to Arm(s): Homebased cardiac rehabilitation program | Intervention Type: OTHER; Name: Traditional cardiac rehabilitation program; Assigned to Arm(s): Homebased cardiac rehabilitation program, Traditional cardiac rehabilitation
B: Arm Label: Telerehabilitation programme; Type: EXPERIMENTAL; Interventions: Device: Telerehabilitation programme | Arm Label: Control group traditional rehabilitation; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Telerehabilitation programme; Assigned to Arm(s): Telerehabilitation programme
C: Arm Label: Home-based exercise rehabilitation; Type: EXPERIMENTAL; Interventions: Other: Exercise rehabilitation | Arm Label: Supervised exercise rehabilitation; Type: ACTIVE_COMPARATOR; Interventions: Other: Exercise rehabilitation | Intervention Type: OTHER; Name: Exercise rehabilitation; Assigned to Arm(s): Home-based exercise rehabilitation, Supervised exercise rehabilitation
D: Arm Label: Treadmill group; Type: ACTIVE_COMPARATOR; Interventions: Other: Exercise training | Arm Label: Exercise groups; Type: ACTIVE_COMPARATOR; Interventions: Other: Exercise training | Arm Label: home-based exercise; Type: ACTIVE_COMPARATOR; Interventions: Other: Exercise training | Intervention Type: OTHER; Name: Exercise training; Assigned to Arm(s): Exercise groups, Treadmill group, home-based exercise

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Hemodialysis-based Interventions to Preserve Cognitive Function
Brief Summary: This is a randomized, controlled trial to slow cognitive decline in adults undergoing hemodialysis (HD). The investigators will test three interventions cognitive training (CT), exercise training (ET), and combined cognitive and exercise training (CT+ET) relative to standard of care (SC).


Options:
A: Arm Label: Cognitive training; Type: ACTIVE_COMPARATOR; Interventions: Other: Cognitive training | Arm Label: Exercise training; Type: ACTIVE_COMPARATOR; Interventions: Other: Exercise training | Arm Label: Combined cognitive and exercise training; Type: ACTIVE_COMPARATOR; Interventions: Other: Combined cognitive and exercise training | Arm Label: Standard of Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Cognitive training; Assigned to Arm(s): Cognitive training | Intervention Type: OTHER; Name: Exercise training; Assigned to Arm(s): Exercise training | Intervention Type: OTHER; Name: Combined cognitive and exercise training; Assigned to Arm(s): Combined cognitive and exercise training
B: Arm Label: pedometer; Type: EXPERIMENTAL; Interventions: Behavioral: pedometer | Arm Label: usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: pedometer; Assigned to Arm(s): pedometer
C: Arm Label: Exercise training; Type: EXPERIMENTAL; Interventions: Other: Exercise training | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Exercise training; Assigned to Arm(s): Exercise training
D: Arm Label: Dopamine Agonist Group; Type: EXPERIMENTAL; Interventions: Other: Dopamine Agonist and Exercise | Arm Label: Placebo Group; Type: PLACEBO_COMPARATOR; Interventions: Other: Dopamine Agonist and Exercise | Intervention Type: OTHER; Name: Dopamine Agonist and Exercise; Assigned to Arm(s): Dopamine Agonist Group, Placebo Group

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Neoadjuvant Phase II Study of TLR9 Agonist CMP-001 in Combination With Nivolumab in Stage IIIB/C/D Melanoma Patients With Clinically Apparent Lymph Node Disease
Brief Summary: The purpose this research study is to determine if the combination of nivolumab and CMP-001 improves the likelihood of eradicating (destroying) disease in the lymph node (pathologic response rate).


Options:
A: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: ipilimumab | Arm Label: B; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: ipilimumab; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): B
B: Arm Label: Nivolumab and CMP-001 Combination; Type: EXPERIMENTAL; Interventions: Drug: CMP-001, Biological: Nivolumab | Intervention Type: DRUG; Name: CMP-001; Assigned to Arm(s): Nivolumab and CMP-001 Combination | Intervention Type: BIOLOGICAL; Name: Nivolumab; Assigned to Arm(s): Nivolumab and CMP-001 Combination
C: Arm Label: Placebo + Vemurafenib; Type: ACTIVE_COMPARATOR; Interventions: Drug: Placebo, Drug: Vemurafenib | Arm Label: Cobimetinib + Vemurafenib; Type: EXPERIMENTAL; Interventions: Drug: Vemurafenib, Drug: Cobimetinib | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo + Vemurafenib | Intervention Type: DRUG; Name: Vemurafenib; Assigned to Arm(s): Cobimetinib + Vemurafenib, Placebo + Vemurafenib | Intervention Type: DRUG; Name: Cobimetinib; Assigned to Arm(s): Cobimetinib + Vemurafenib
D: Arm Label: Arm A: Nivolumab+Placebo for Ipilimumab+Placebo for Nivolumab; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab, Biological: Placebo for Nivolumab, Biological: Placebo for Ipilimumab | Arm Label: Arm B: Nivolumab+Ipilimumab+Placebo for Nivolumab; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab, Biological: Ipilimumab, Biological: Placebo for Nivolumab | Arm Label: Arm C: Ipilimumab+Placebo for Nivolumab; Type: EXPERIMENTAL; Interventions: Biological: Ipilimumab, Biological: Placebo for Nivolumab | Intervention Type: BIOLOGICAL; Name: Nivolumab; Assigned to Arm(s): Arm A: Nivolumab+Placebo for Ipilimumab+Placebo for Nivolumab, Arm B: Nivolumab+Ipilimumab+Placebo for Nivolumab | Intervention Type: BIOLOGICAL; Name: Ipilimumab; Assigned to Arm(s): Arm B: Nivolumab+Ipilimumab+Placebo for Nivolumab, Arm C: Ipilimumab+Placebo for Nivolumab | Intervention Type: BIOLOGICAL; Name: Placebo for Nivolumab; Assigned to Arm(s): Arm A: Nivolumab+Placebo for Ipilimumab+Placebo for Nivolumab, Arm B: Nivolumab+Ipilimumab+Placebo for Nivolumab, Arm C: Ipilimumab+Placebo for Nivolumab | Intervention Type: BIOLOGICAL; Name: Placebo for Ipilimumab; Assigned to Arm(s): Arm A: Nivolumab+Placebo for Ipilimumab+Placebo for Nivolumab

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Program Evaluation of an In-school Daily Physical Activity Initiative for Children and Youth
Brief Summary: The school system is one setting in which children's physical activity levels may be increased through daily physical activity (DPA) policies and initiatives. Adherence to DPA policies is typically poor and results are limited in regard to the associated benefits for participating children. Therefore, the purpose of this study was to evaluate a range of psychosocial outcomes following a community-led, in-school DPA initiative for 9-14 year old children and youth. This program evaluation examined the impact of a DPA program consisting of 20 minutes of teacher-led DPA for 20 consecutive weeks. Student outcomes were measured using a questionnaire administered at three time points: baseline, mid-intervention, and post-intervention. A teacher questionnaire regarding program adherence and student behaviour was completed at post-intervention.


Options:
A: Arm Label: control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: lifestyle counseling; Type: EXPERIMENTAL; Interventions: Behavioral: lifestyle counseling | Intervention Type: BEHAVIORAL; Name: lifestyle counseling; Assigned to Arm(s): lifestyle counseling
B: Intervention Type: BEHAVIORAL; Name: Switch active lifestyles brought to you by MediaWise; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Switch active lifestyles from MediaWise; Assigned to Arm(s): N/A
C: Arm Label: Daily physical activity intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Daily physical activity intervention | Arm Label: Control - treatment as usual; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Daily physical activity intervention; Assigned to Arm(s): Daily physical activity intervention
D: Arm Label: New Moves Intervention Group; Type: EXPERIMENTAL; Interventions: Behavioral: New Moves | Arm Label: control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: New Moves; Assigned to Arm(s): New Moves Intervention Group

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Program Evaluation of an In-school Daily Physical Activity Initiative for Children and Youth
Brief Summary: The school system is one setting in which children's physical activity levels may be increased through daily physical activity (DPA) policies and initiatives. Adherence to DPA policies is typically poor and results are limited in regard to the associated benefits for participating children. Therefore, the purpose of this study was to evaluate a range of psychosocial outcomes following a community-led, in-school DPA initiative for 9-14 year old children and youth. This program evaluation examined the impact of a DPA program consisting of 20 minutes of teacher-led DPA for 20 consecutive weeks. Student outcomes were measured using a questionnaire administered at three time points: baseline, mid-intervention, and post-intervention. A teacher questionnaire regarding program adherence and student behaviour was completed at post-intervention.


Options:
A: Arm Label: School based intervention; Type: EXPERIMENTAL; Interventions: Behavioral: integrated program of nutrition, activity, behavior, and promotion | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: integrated program of nutrition, activity, behavior, and promotion; Assigned to Arm(s): School based intervention
B: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Physical activity guidance, Behavioral: Health education | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Physical activity guidance; Assigned to Arm(s): Intervention | Intervention Type: BEHAVIORAL; Name: Health education; Assigned to Arm(s): Intervention
C: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Short Intervention; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Short-term educational program | Arm Label: Long Intervention; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Long-term educational program | Intervention Type: BEHAVIORAL; Name: Long-term educational program; Assigned to Arm(s): Long Intervention | Intervention Type: BEHAVIORAL; Name: Short-term educational program; Assigned to Arm(s): Short Intervention
D: Arm Label: Daily physical activity intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Daily physical activity intervention | Arm Label: Control - treatment as usual; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Daily physical activity intervention; Assigned to Arm(s): Daily physical activity intervention

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Low Energy Shock Wave for the Treatment of Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS) - a Randomized, Double-blind, Placebo-controlled, Prospective Study
Brief Summary: To investigate the efficacy and safety of LESW on participants with IC/BPS


Options:
A: Arm Label: adalimumab; Type: EXPERIMENTAL; Interventions: Drug: Adalimumab | Arm Label: Inactive drug; Type: PLACEBO_COMPARATOR; Interventions: Other: inactive drug | Intervention Type: DRUG; Name: Adalimumab; Assigned to Arm(s): adalimumab | Intervention Type: OTHER; Name: inactive drug; Assigned to Arm(s): Inactive drug
B: Arm Label: ASP6294; Type: EXPERIMENTAL; Interventions: Drug: ASP6294 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: ASP6294; Assigned to Arm(s): ASP6294 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Device: Placebo | Arm Label: Low energy shock wave; Type: EXPERIMENTAL; Interventions: Device: Low energy shock wave | Intervention Type: DEVICE; Name: Low energy shock wave; Assigned to Arm(s): Low energy shock wave | Intervention Type: DEVICE; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Life-Stress Interview; Type: EXPERIMENTAL; Interventions: Behavioral: Life-Stress Interview | Arm Label: Wait-list Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Life-Stress Interview; Assigned to Arm(s): Life-Stress Interview

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III, Multicenter, Randomized, Double-Masked, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Patients With Diabetic Macular Edema (YOSEMITE)
Brief Summary: This study will evaluate the efficacy, safety, and pharmacokinetics of faricimab administered at 8-week intervals or as specified in the protocol following treatment initiation, compared with aflibercept once every 8 weeks (Q8W), in participants with diabetic macular edema (DME).


Options:
A: Arm Label: Ranibizumab 0.3 mg; Type: EXPERIMENTAL; Interventions: Drug: Ranibizumab | Arm Label: Ranibizumab 0.5 mg; Type: EXPERIMENTAL; Interventions: Drug: Ranibizumab | Arm Label: Sham injection/ranibizumab 0.5 mg; Type: SHAM_COMPARATOR; Interventions: Drug: Sham injection | Intervention Type: DRUG; Name: Ranibizumab; Assigned to Arm(s): Ranibizumab 0.3 mg, Ranibizumab 0.5 mg | Intervention Type: DRUG; Name: Sham injection; Assigned to Arm(s): Sham injection/ranibizumab 0.5 mg
B: Arm Label: A: Faricimab 6 mg Q8W; Type: EXPERIMENTAL; Interventions: Drug: Faricimab, Procedure: Sham Procedure | Arm Label: B: Faricimab 6 mg PTI; Type: EXPERIMENTAL; Interventions: Drug: Faricimab, Procedure: Sham Procedure | Arm Label: C: Aflibercept 2 mg Q8W; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aflibercept, Procedure: Sham Procedure | Intervention Type: DRUG; Name: Aflibercept; Assigned to Arm(s): C: Aflibercept 2 mg Q8W | Intervention Type: DRUG; Name: Faricimab; Assigned to Arm(s): A: Faricimab 6 mg Q8W, B: Faricimab 6 mg PTI | Intervention Type: PROCEDURE; Name: Sham Procedure; Assigned to Arm(s): A: Faricimab 6 mg Q8W, B: Faricimab 6 mg PTI, C: Aflibercept 2 mg Q8W
C: Arm Label: SS-PRP arm; Type: ACTIVE_COMPARATOR; Interventions: Drug: Intravitreal Ranibizumabe, Drug: panfotocoagulation (PRP) single shoot (ETDRS) | Arm Label: MS-PRP arm; Type: EXPERIMENTAL; Interventions: Drug: Intravitreal Ranibizumabe, Drug: panfotocoagulation (PASCAL) | Arm Label: IVR arm; Type: OTHER; Interventions: Drug: Intravitreal Ranibizumabe | Intervention Type: DRUG; Name: Intravitreal Ranibizumabe; Assigned to Arm(s): IVR arm, MS-PRP arm, SS-PRP arm | Intervention Type: DRUG; Name: panfotocoagulation (PASCAL); Assigned to Arm(s): MS-PRP arm | Intervention Type: DRUG; Name: panfotocoagulation (PRP) single shoot (ETDRS); Assigned to Arm(s): SS-PRP arm
D: Arm Label: 7 days; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bevacizumab | Arm Label: 20 days; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bevacizumab | Arm Label: sham; Type: SHAM_COMPARATOR; Interventions: Other: sham | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): 20 days, 7 days | Intervention Type: OTHER; Name: sham; Assigned to Arm(s): sham

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III, Multicenter, Randomized, Double-Masked, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Patients With Diabetic Macular Edema (RHINE)
Brief Summary: This study will evaluate the efficacy, safety, and pharmacokinetics of faricimab administered at 8-week intervals or as specified in the protocol following treatment initiation, compared with aflibercept once every 8 weeks (Q8W), in participants with diabetic macular edema (DME).


Options:
A: Arm Label: SS-PRP arm; Type: ACTIVE_COMPARATOR; Interventions: Drug: Intravitreal Ranibizumabe, Drug: panfotocoagulation (PRP) single shoot (ETDRS) | Arm Label: MS-PRP arm; Type: EXPERIMENTAL; Interventions: Drug: Intravitreal Ranibizumabe, Drug: panfotocoagulation (PASCAL) | Arm Label: IVR arm; Type: OTHER; Interventions: Drug: Intravitreal Ranibizumabe | Intervention Type: DRUG; Name: Intravitreal Ranibizumabe; Assigned to Arm(s): IVR arm, MS-PRP arm, SS-PRP arm | Intervention Type: DRUG; Name: panfotocoagulation (PASCAL); Assigned to Arm(s): MS-PRP arm | Intervention Type: DRUG; Name: panfotocoagulation (PRP) single shoot (ETDRS); Assigned to Arm(s): SS-PRP arm
B: Arm Label: ESBA1008; Type: EXPERIMENTAL; Interventions: Drug: ESBA1008 solution | Arm Label: EYLEA; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aflibercept | Intervention Type: DRUG; Name: ESBA1008 solution; Assigned to Arm(s): ESBA1008 | Intervention Type: DRUG; Name: Aflibercept; Assigned to Arm(s): EYLEA
C: Arm Label: A: Faricimab 6 mg Q8W; Type: EXPERIMENTAL; Interventions: Drug: Faricimab, Procedure: Sham Procedure | Arm Label: B: Faricimab 6 mg PTI; Type: EXPERIMENTAL; Interventions: Drug: Faricimab, Procedure: Sham Procedure | Arm Label: C: Aflibercept 2 mg Q8W; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aflibercept, Procedure: Sham Procedure | Intervention Type: DRUG; Name: Aflibercept; Assigned to Arm(s): C: Aflibercept 2 mg Q8W | Intervention Type: DRUG; Name: Faricimab; Assigned to Arm(s): A: Faricimab 6 mg Q8W, B: Faricimab 6 mg PTI | Intervention Type: PROCEDURE; Name: Sham Procedure; Assigned to Arm(s): A: Faricimab 6 mg Q8W, B: Faricimab 6 mg PTI, C: Aflibercept 2 mg Q8W
D: Arm Label: A: Faricimab 6 mg Q8W; Type: EXPERIMENTAL; Interventions: Drug: Faricimab, Procedure: Sham Procedure | Arm Label: B: Faricimab 6 mg PTI; Type: EXPERIMENTAL; Interventions: Drug: Faricimab, Procedure: Sham Procedure | Arm Label: C: Aflibercept 2 mg Q8W; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aflibercept, Procedure: Sham Procedure | Intervention Type: DRUG; Name: Aflibercept; Assigned to Arm(s): C: Aflibercept 2 mg Q8W | Intervention Type: DRUG; Name: Faricimab; Assigned to Arm(s): A: Faricimab 6 mg Q8W, B: Faricimab 6 mg PTI | Intervention Type: PROCEDURE; Name: Sham Procedure; Assigned to Arm(s): A: Faricimab 6 mg Q8W, B: Faricimab 6 mg PTI, C: Aflibercept 2 mg Q8W

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multi-Center, Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of BMS-986165 in Subjects With Moderate-to-Severe Plaque Psoriasis
Brief Summary: The purpose of this study is to investigate the experimental medication BMS-986165 compared to placebo and a currently available treatment in participants with moderate to severe plaque psoriasis.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: 4; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 4
B: Arm Label: 210 mg brodalumab; Type: EXPERIMENTAL; Interventions: Drug: 210 mg brodalumab, Drug: placebo | Arm Label: 140 mg brodalumab; Type: EXPERIMENTAL; Interventions: Drug: 140 mg brodalumab, Drug: placebo | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: 210 mg brodalumab, Drug: placebo | Intervention Type: DRUG; Name: 210 mg brodalumab; Assigned to Arm(s): 210 mg brodalumab, placebo | Intervention Type: DRUG; Name: 140 mg brodalumab; Assigned to Arm(s): 140 mg brodalumab | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 140 mg brodalumab, 210 mg brodalumab, placebo
C: Arm Label: BMS-986165; Type: EXPERIMENTAL; Interventions: Drug: BMS-986165 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: Apremilast; Type: ACTIVE_COMPARATOR; Interventions: Drug: Apremilast | Intervention Type: DRUG; Name: BMS-986165; Assigned to Arm(s): BMS-986165 | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Apremilast; Assigned to Arm(s): Apremilast
D: Arm Label: Placebo (Part A); Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo for risankizumab | Arm Label: Risankizumab 75 mg (Part A); Type: EXPERIMENTAL; Interventions: Drug: risankizumab, Drug: placebo for risankizumab | Arm Label: Risankizumab 150 mg (Part A); Type: EXPERIMENTAL; Interventions: Drug: risankizumab | Intervention Type: DRUG; Name: risankizumab; Assigned to Arm(s): Risankizumab 150 mg (Part A), Risankizumab 75 mg (Part A) | Intervention Type: DRUG; Name: placebo for risankizumab; Assigned to Arm(s): Placebo (Part A), Risankizumab 75 mg (Part A)

Answer: C